Characterisation of interface astroglial scarring in the human brain after blast exposure: a post-mortem case series.
No evidence-based guidelines are available for the definitive diagnosis or directed treatment of most blast-associated traumatic brain injuries, partly because the underlying pathology is unknown. Moreover, few neuropathological studies have addressed whether blast exposure produces unique lesions in the human brain, and if those lesions are comparable with impact-induced traumatic brain injury. We aimed to test the hypothesis that blast exposure produces unique patterns of damage, differing from that associated with impact-induced, non-blast traumatic brain injuries.



In this post-mortem case series, we investigated several features of traumatic brain injuries, using clinical histopathology techniques and markers, in brain specimens from male military service members with chronic blast exposures and from those who had died shortly after severe blast exposures. We then compared these results with those from brain specimens from male civilian (ie, non-military) cases with no history of blast exposure, including cases with and without chronic impact traumatic brain injuries and cases with chronic exposure to opiates, and analysed the limited associated clinical histories of all cases. Brain specimens had been archived in tissue banks in the USA.



We analysed brain specimens from five cases with chronic blast exposure, three cases with acute blast exposure, five cases with chronic impact traumatic brain injury, five cases with exposure to opiates, and three control cases with no known neurological disorders. All five cases with chronic blast exposure showed prominent astroglial scarring that involved the subpial glial plate, penetrating cortical blood vessels, grey-white matter junctions, and structures lining the ventricles; all cases of acute blast exposure showed early astroglial scarring in the same brain regions. All cases of chronic blast exposure had an antemortem diagnosis of post traumatic stress disorder. The civilian cases, with or without history of impact traumatic brain injury or a history of opiate use, did not have any astroglial scarring in the brain regions analysed.



The blast exposure cases showed a distinct and previously undescribed pattern of interface astroglial scarring at boundaries between brain parenchyma and fluids, and at junctions between grey and white matter. This distinctive pattern of scarring may indicate specific areas of damage from blast exposure consistent with the general principles of blast biophysics, and further, could account for aspects of the neuropsychiatric clinical sequelae reported. The generalisability of these findings needs to be explored in future studies, as the number of cases, clinical data, and tissue availability were limited.



Defense Health Program of the United States Department of Defense.
Department of Pathology, F Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Center for Neuroscience and Regenerative Medicine, Bethesda, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Sharon Baughman
SB
Shively
The Joint Pathology Center, Defense Health Agency, Silver Spring, MD, USA.
Iren
I
Horkayne-Szakaly
The Joint Pathology Center, Defense Health Agency, Silver Spring, MD, USA.
Robert V
RV
Jones
Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA.
James P
JP
Kelly
Department of Anatomy, Physiology and Genetics, F Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Center for Neuroscience and Regenerative Medicine, Bethesda, MD, USA.
Regina C
RC
Armstrong
Department of Pathology, F Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; Center for Neuroscience and Regenerative Medicine, Bethesda, MD, USA. Electronic address: daniel.perl@usuhs.edu.
Daniel P
DP
Perl
D000328:Adult; D000368:Aged; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D001253:Astrocytes / Q000473:pathology*; D001344:Autopsy; D001753:Blast Injuries / Q000150:complications*; D001921:Brain / Q000378:metabolism / Q000473:pathology; D000070642:Brain Injuries, Traumatic / Q000209:etiology*; D002921:Cicatrix / Q000209:etiology* / Q000473:pathology*; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D039781:PubMed / Q000706:statistics & numerical data; D014481:United States; D055815:Young Adult; D000097382:CD68 Molecule
D016564:Amyloid beta-Protein Precursor; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D005904:Glial Fibrillary Acidic Protein; C067980:CD68 antigen, human; D000097382:CD68 Molecule